Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety risks and restrictions on this drug still leave an unmet patient need, one that a growing number of biotechs are vying to fill.

Braveheart Bio is developing a drug whose clinical data to date show the potential for advantages in safety along with greater patient and physician convenience. San Francisco-based Braveheart is preparing to advance its in-licensed molecule to Phase 3 testing and on Wednesday, the startup unveiled $185 million for this global clinical trial on track to begin in 2026.

In obstructive hypertrophic cardiomyopathy, or oHCM, heart muscle becomes thicker, making it harder f

See Full Page